Holen Sie sich die Stockscreener-App
35.11
1.01%
0.35
Schlusskurs vom Vortag:
$34.76
Offen:
$34.87
24-Stunden-Volumen:
1.20M
Relative Volume:
0.73
Marktkapitalisierung:
$5.59B
Einnahmen:
$705.14M
Nettoeinkommen (Verlust:
$-453.90M
KGV:
-11.55
EPS:
-3.04
Netto-Cashflow:
$-551.29M
1W Leistung:
+8.26%
1M Leistung:
+7.11%
6M Leistung:
-5.49%
1J Leistung:
-12.33%
1-Tages-Spanne:
$34.72
$35.84
1-Wochen-Bereich:
$32.00
$35.84
52-Wochen-Spanne:
$23.95
$52.34
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Firmenname
Ionis Pharmaceuticals Inc
Sektor
Branche
Telefon
(760) 931-9200
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Vergleichen Sie IONS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
35.11 | 5.16B | 705.14M | -453.90M | -551.29M | -3.04 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Fortgesetzt | Jefferies | Buy |
| 2024-06-14 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Strong Buy |
| 2023-07-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-05-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2022-12-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-01 | Eingeleitet | Citigroup | Sell |
| 2022-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Hochstufung | UBS | Sell → Neutral |
| 2021-03-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Eingeleitet | UBS | Sell |
| 2020-12-15 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-02 | Eingeleitet | The Benchmark Company | Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Bestätigt | Stifel | Hold |
| 2018-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Fortgesetzt | Goldman | Sell |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-08-09 | Bestätigt | Stifel | Hold |
| 2017-03-10 | Herabstufung | Goldman | Neutral → Sell |
| 2016-12-28 | Bestätigt | BMO Capital Markets | Outperform |
| 2016-12-27 | Bestätigt | Leerink Partners | Mkt Perform |
Alle ansehen
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
10 Promising Biotech Stocks to Invest in (June 2025) - Securities.io
Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report? - Yahoo Finance
We Discuss Why Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Compensation May Be Closely Reviewed - simplywall.st
Transthyretin Amyloid Cardiomyopathy Treatment Market Deep Research ReportPfizer, Ionis Pharmaceuticals - openPR.com
Type 2 Diabetes Pipeline 2025: Therapies Under Investigation, - openPR.com
Ionis Pharmaceuticals’ SWOT analysis: RNA therapeutics firm faces pivotal year for stock - Investing.com
Angioedema Treatment Market Insights and Forecast from 2025 - openPR.com
Hereditary Angioedema Drugs Market 2034: EMA, PDMA, FDA - openPR.com
Ionis’ olezarsen shows new promise with strong Phase III results - The Pharma Letter
December 2027 Options Now Available For Ionis Pharmaceuticals (IONS) - Nasdaq
Ionis reports success in olezarsen trial for high triglycerides - Yahoo
Treatment-Resistant Hypertension Market: Epidemiology, - openPR.com
Ionis Pharmaceuticals (NASDAQ:IONS) Earns Buy Rating from HC Wainwright - Defense World
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study - MSN
Hereditary Angioedema Market Set to Grow Substantially Through - openPR.com
Analysts Offer Insights on Healthcare Companies: Strata Skin Sciences (SSKN), Ionis Pharmaceuticals (IONS) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
Transcript : Ionis Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 08 - marketscreener.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Purchased by Janus Henderson Group PLC - Defense World
Ionis reports positive data from study of olezarsen for hypertriglyceridemia - Clinical Trials Arena
Ionis Pharmaceuticals (IONS) Receives Buy Rating from HC Wainwri - GuruFocus
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 14 Analysts - Benzinga
In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes - insights.citeline.com
Ionis reports positive results for olezarsen in study By Investing.com - Investing.com South Africa
Ionis reports positive results for olezarsen in study - Investing.com Australia
Olezarsen Cuts Triglyceride Levels at 6 Months in Essence Study - HCPLive
Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides - BioSpace
Spinal Muscular Atrophy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme - Barchart.com
Ionis Pharmaceuticals Says Olezarsen Trial Meets Primary Endpoint, All Key Secondary Endpoints - marketscreener.com
Ionis Pharmaceuticals (IONS) Reports Positive Results from Olezarsen Study | IONS Stock News - GuruFocus
Ionis announces positive topline results from Essence study of o - GuruFocus
Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides | IONS Stock News - GuruFocus
Ionis Pharmaceuticals (IONS) Reports Positive Results from Oleza - GuruFocus
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stake Reduced by Comerica Bank - Defense World
Drug developer stocks fall as companies navigate clinical roadblocks - BioWorld MedTech
Beta thalassemia Market: Epidemiology, Therapies, Companies, - openPR.com
Transcript : Ionis Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 09 - marketscreener.com
Familial Chylomicronemia Syndrome Drugs Market Size in 7MM - openPR.com
Polycythemia Vera Drugs Market Size in 7MM is expected to grow at - openPR.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Ionis Pharmaceuticals, Inc. (IONS): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential - Insider Monkey
Billionaire Glenn Russell Dubin’s 10 Stock Picks with Huge Upside Potential - Insider Monkey
Bennett C. Frank of Ionis Pharmaceuticals sells $222,113 in stock - MSN
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - Yahoo Finance
Ionis to host 2025 virtual Annual Meeting of Stockholders | IONS Stock News - GuruFocus
Ionis to host 2025 virtual Annual Meeting of Stockholders - Business Wire
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com
Spinocerebellar Ataxias Pipeline 2025: Comprehensive - openPR.com
Oligonucleotide Delivery System Market Key Players Analysis - openPR.com
Analysts Just Made A Sizeable Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Forecasts - Yahoo Finance
Ionis Pharmaceuticals targets $750M revenue for 2025 with multiple launches underway - MSN
Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):